Wall Street Zen Upgrades Sanofi (NASDAQ:SNY) to Buy

Sanofi (NASDAQ:SNY) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also commented on SNY. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Morgan Stanley set a $49.00 price target on shares of Sanofi in a report on Wednesday, July 8th. Finally, BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Sanofi presently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Price Performance

SNY stock opened at $43.08 on Friday. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $104.44 billion, a PE ratio of 22.55, a PEG ratio of 1.15 and a beta of 0.35. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68. The stock has a 50-day simple moving average of $43.43 and a two-hundred day simple moving average of $45.19.

Institutional Investors Weigh In On Sanofi

Hedge funds have recently bought and sold shares of the stock. Advisory Services Network LLC increased its holdings in shares of Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after buying an additional 210 shares during the last quarter. Savant Capital LLC lifted its holdings in shares of Sanofi by 2.7% during the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after acquiring an additional 225 shares during the last quarter. Wesbanco Bank Inc. lifted its holdings in shares of Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after acquiring an additional 230 shares during the last quarter. IFG Advisory LLC grew its position in Sanofi by 2.7% in the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after acquiring an additional 244 shares in the last quarter. Finally, Cohen Investment Advisors LLC grew its position in Sanofi by 2.9% in the first quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after acquiring an additional 263 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter earnings of $1.19 per share, exceeding the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, above expectations of $13.02 billion. Sanofi quarterly earnings report
• Positive Sentiment: Strong demand for blockbuster immunology drug Dupixent drove the results, with quarterly sales surpassing €5 billion for the first time. The performance led Sanofi to raise its 2026 outlook, targeting roughly 10% sales growth excluding currency effects and slightly faster growth in business earnings per share. Sanofi raises sales outlook on Dupixent strength
• Neutral Sentiment: Unusually high options activity showed traders purchased 4,046 call options, 74% above average daily volume. This may indicate increased bullish speculation, but it does not necessarily signal a change in the company’s fundamentals.
• Negative Sentiment: Management acknowledged that weak decision-making and execution hurt the pipeline. The new CEO plans to overhaul and prioritize R&D, raising concerns about the timing and strength of future product launches. Sanofi discusses pipeline and R&D discipline
• Negative Sentiment: The positive earnings and guidance news was overshadowed by pipeline setbacks, leaving investors focused on whether Dupixent’s momentum can offset longer-term portfolio risks. Sanofi beats earnings but faces pipeline setbacks

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.